Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074135 · ClinicalTrials.gov registry record · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
A Phase 2 study of Neuroendocrine Tumors and Von Hippel-Lindau Disease, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 740
- Enrollment target
- 1
- Study location
NCT04074135: Recruiting Phase 2 study of Neuroendocrine Tumors and Von Hippel-Lindau Disease, sponsored by National Cancer Institute (NCI).
NCT04074135 is a Phase 2 study of Neuroendocrine Tumors and Von Hippel-Lindau Disease that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 740 participants, above the 166-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (346% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04074135, a Phase 2 study of Neuroendocrine Tumors and Von Hippel-Lindau Disease, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 740 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: People with von Hippel-Lindau (VHL) can have problems with a variety of organs, such as the pancreas. The disease can cause tumors of the pancreas. This can result in life-threatening complications. Researchers want to learn more about these pancreatic tumors and how to better detect them. This may help them design better future treatment and care for people with VHL disease. Objective: To better understand VHL disease that affects the pancreas and to test whether adding a certain type of scan (68-Gallium DOTATATE PET/CT) can further detect tumors. Eligibility: People ages 12 and older with VHL that causes tumors and cysts to grow in the pancreas Design: Participants will be screened with their medical records and imaging studies. Participants will have an initial evaluation: Participants will have their body examined by different doctors. This will depend on what types of symptoms they have. Participants will have blood and urine tests Participants will have images made of their body using one or more machines: They made have a CT or PET/CT scan in which they lie on a table that moves through a big ring. They may have an MRI in which they lie on a table that moves into a big tube. They may have an ultrasound that uses a small stick that produces sound waves to look at the body. After the first visit, participants will be asked to return to the NIH. Some of the tests performed at the first visit will be repeated. Depending on their disease status, visits will be once a year or every 2 years for life.
Primary Outcome
Characterization of the natural and clinical histories of VHL pancreatic neuroendocrine tumors and cystic lesions
Conditions Studied
Interventions
- DRUG 68-Gallium DOTATATE
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2036-07-01 |
| Phase | Phase 2 |
What NCT04074135 shows while recruiting
NCT04074135 is an interventional study that assigns participants to a tested intervention. The registered 740 participants enrollment target is mid-sized for trials with a published cap, above the 166-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (346% higher).
The record links to 3 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which 68-Gallium DOTATATE is the first listed.
NCT04074135 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04074135 about?
NCT04074135 is a clinical study titled "Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors". Background: People with von Hippel-Lindau (VHL) can have problems with a variety of organs, such as the pancreas. The disease can cause tumors of the pancreas. This can result in life-threatening complications. Researchers want to learn more about these pancreatic tumors and how to better detect th...
What is the current status of trial NCT04074135?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 740 participants. The study started on 2020-06-02. Estimated completion is 2036-07-01.
What conditions does trial NCT04074135 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Von Hippel-Lindau Disease, VHL Pancreatic Neuroendocrine Tumors.
What interventions are being tested in trial NCT04074135?
The interventions under investigation include: 68-Gallium DOTATATE (DRUG).
Who is sponsoring clinical trial NCT04074135?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04074135 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04074135's enrollment target sits among peer trials
740 3rd of 52 higher than 50 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- NCT06172478 · 740 participants · Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- NCT06697301 · 740 participants · Phase 2
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI